CFO
CCCC icon

Callan Family Office’s C4 Therapeutics CCCC Stock Holding History

Callan Family Office’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4K Sell
19,146
-12,597
-40% -$29.7K ﹤0.01% 1110
2025
Q4 		$60.6K Buy
+31,743
New +$75.2K ﹤0.01% 1088

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Callan Family Office's CCCC Position: Q1 2026 in Review

Callan Family Office reduced its C4 Therapeutics (CCCC) stake by 40% in Q1 2026, selling an estimated $29.7K and leaving 19,146 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Callan Family Office first reported a position in CCCC in Q4 2025 and has held it in 2 quarters since. The position peaked at $60.6K in Q4 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Callan Family Office held 19,146 shares of C4 Therapeutics worth $50.4K as of Q1 2026.
  • Callan Family Office sold 12,597 C4 Therapeutics shares in Q1 2026, an estimated $29.7K.
  • C4 Therapeutics made up ﹤0.01% of Callan Family Office's portfolio in Q1 2026, its #1110 holding.
  • Callan Family Office first reported a position in C4 Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Callan Family Office's C4 Therapeutics position peaked at $60.6K in Q4 2025.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.